U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Advisory Committee on Immunization Practices (ACIP)

CDC Stacks Public Health Publications

The ACIP is a group of medical and public health experts that develops recommendations on the use of vaccines in the civilian population of the United States. The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia to make vaccine recommendations. Meetings are open to the public and available online via webcast. More information on ACIP is available at: https://www.cdc.gov/vaccines/acip/index.html.

(93)
(134)
(235)
(276)
(178)
(127)
(138)
(113)
(96)
(84)
(115)
(117)
(125)
(16)
(24)
(16)
(19)
(13)
(17)
(9)
(8)
(15)
(11)
(6)
(10)
(10)
(5)
(10)
(11)
(5)
(8)
(9)
(6)
(9)
(8)
(7)
(6)
(10)
(5)
(6)
(5)
(6)
(6)
(5)
(5)
(6)
(9)
(3)
(8)
(4)
(3)
(2)
(5)
(3)
(2)
(4)
(3)
(3)
(2)
(2)
(1)
0 of 61
(12)
(32)
(108)
(38)
(11)
(1)
(1)
(49)
(1)
(51)
(49)
(17)
(9)
(1293)
(497)
(7)
0 of 16
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(5)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(449)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 46
(1)
(1)
(1)
0 of 3
(10)
(5)
(1)
(4)
(2)
(1)
(1)
(3)
(1)
(5)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(138)
(1)
(158)
(1)
(33)
(66)
(1)
(1)
(73)
(19)
(2)
(12)
(19)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(31)
(2)
(3)
(1)
(2)
(2)
(3)
(6)
(1)
(1)
(10)
(1)
(3)
(2)
(2)
(14)
(2)
(2)
(3)
(5)
(2)
(1)
(9)
(3)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(1)
(5)
(3)
(1)
(7)
(1)
(10)
(1)
(1)
(10)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(12)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(12)
(2)
(2)
(1)
(3)
(9)
(1)
(6)
(1)
(1)
(6)
(2)
(2)
(10)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(3)
(3)
(1)
(11)
(2)
(2)
(4)
(1)
(3)
(13)
(8)
(158)
(111)
(1)
(2)
(2)
(1)
(1)
(11)
(1)
(1)
(10)
(2)
(7)
(2)
(1)
(1)
(1)
(7)
(15)
(4)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(20)
(5)
(199)
(44)
(4)
(3)
(1)
(19)
(2)
(3)
(2)
(82)
(1)
(257)
(6)
(21)
(2)
(1)
(3)
(1)
(1)
(8)
(1)
(4)
(2)
(1)
(1)
(118)
(7)
(5)
(3)
(1)
(1)
(1)
(3)
(1)
(1)
(4)
(35)
(2)
(1)
(16)
(2)
(12)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(22)
(1)
(2)
(2)
(10)
(2)
(2)
(2)
(3)
(1)
(1)
(2)
(23)
(10)
(3)
(1)
(5)
(1)
(1)
(1)
(15)
(1)
(3)
(1)
(9)
(1)
(2)
(4)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(1)
(4)
(1)
(1)
(1)
(17)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(3)
(1)
(1)
(3)
(2)
(1)
(2)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(4)
(3)
(9)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(54)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(21)
(3)
(1)
(5)
(1)
(1)
(15)
(1)
(56)
(1)
(2)
(5)
(1)
(2)
(2)
(1)
(1)
(3)
(5)
(2)
(1)
(15)
(1)
(1)
(2)
(2)
(1)
(3)
(1)
(33)
(2)
(1)
(3)
(2)
(3)
(1)
(19)
(2)
(2)
(4)
(4)
(2)
(1)
(2)
(1)
(2)
(5)
(7)
(1)
(1)
(1)
(7)
(9)
(9)
(1)
(1)
(3)
(1)
(26)
(3)
(1)
(2)
(1)
(1)
(10)
(1)
(2)
(1)
(1)
(39)
(2)
(1)
(1)
(1)
(3)
(4)
(1)
(2)
(3)
(1)
(35)
(1)
(1)
(1)
(7)
(1)
(8)
(1)
(2)
(10)
(11)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(167)
(1)
(1)
(5)
(1)
(1)
(4)
(343)
(6)
(3)
(76)
(2)
(2)
(1)
(1)
(1)
(2)
(50)
(6)
(4)
(321)
(1)
(1)
(1)
(192)
(1)
(2)
(17)
(3)
(2)
(3)
(3)
(1)
(1)
(1)
(1)
(6)
(1)
(6)
(110)
(1)
(71)
(1)
(6)
(2)
(3)
(2)
(1)
(1)
(39)
(1)
(10)
(1)
(11)
(4)
(26)
(15)
(2)
(1)
(2)
(1)
(3)
(10)
(4)
(15)
(2)
(13)
(2)
(18)
(6)
(2)
(1)
(1)
(2)
(2)
(4)
(173)
(18)
(2)
(1)
(11)
(5)
(2)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(1)
(1)
(1)
(1)
(12)
(3)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(10)
(1)
(4)
(1)
(1)
(31)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(3)
(2)
(6)
(1)
(13)
(4)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(42)
(1)
(2)
(8)
(1)
(1)
(11)
(1)
(1)
(6)
(28)
(1)
(1)
(1)
(2)
(1)
(7)
(1)
(9)
(1)
(2)
(1)
(2)
(1)
(2)
(3)
(4)
(1)
(1)
(3)
(14)
(3)
(1)
(10)
(2)
(1)
(104)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(71)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(15)
(1)
(3)
(2)
(3)
(3)
(4)
(15)
(12)
(3)
(2)
(4)
(3)
(1)
(6)
(1)
(7)
(1)
(1)
(5)
(1)
(13)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(4)
(1)
(1)
(1)
(4)
(1)
(7)
(1)
(3)
(6)
(2)
(1)
(2)
(1)
(2)
(1)
(7)
(1)
(1)
(1)
(2)
(1)
(1)
(29)
(1)
(152)
(1)
(5)
(1)
(1)
(1)
(3)
(2)
(56)
(1)
(1)
(34)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(56)
(1)
(2)
(1)
(6)
(1)
(1)
(1)
(35)
(2)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(17)
(1)
(1)
(8)
(1)
(91)
(3)
(1)
(2)
(4)
(1)
(1)
(11)
(2)
(3)
(1)
(3)
(1)
(4)
(2)
(6)
(2)
(2)
(1)
(8)
(2)
(1)
(5)
(1)
(10)
(13)
(1)
(6)
(1)
(2)
(1)
(6)
(1)
(35)
(1)
(9)
(1)
(64)
(1)
(6)
(3)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(26)
(1)
(1)
(3)
(1)
(1)
(4)
(1)
(1)
(3)
(3)
(1)
(16)
(1)
(1)
(1)
(4)
(2)
(14)
(1)
(1)
(4)
(3)
(2)
(11)
(1)
(1)
(1)
(4)
(5)
(2)
(4)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(10)
(5)
(2)
(1)
(53)
(13)
(4)
(48)
(10)
(13)
(1)
(1)
(1)
(2)
(1)
(4)
(18)
(12)
(1)
(1)
(3)
(9)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(2)
(32)
(5)
(2)
(13)
(5)
(1)
(1)
(2)
(19)
(1)
(6)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(11)
(2)
(1)
(4)
(2)
(1)
(1)
(2)
(1)
(1)
(26)
(2)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(3)
(2)
(8)
(1)
(5)
(4)
(8)
(5)
(1)
(1)
(1)
(1)
(1)
(21)
(1)
(1)
(2)
(1)
(7)
(3)
(2)
(4)
(2)
(1)
(2)
(2)
(1)
(1)
(630)
(17)
(2)
(1)
(1)
(5)
(1)
(1)
(24)
(22)
(4)
(4)
(1)
(1)
(13)
(379)
(1)
(28)
(23)
(23)
(1)
(1)
(1)
(21)
(1)
(1)
(9)
(2)
(51)
(2)
(1)
(11)
(18)
(2)
(2)
(5)
(3)
(12)
(2)
(170)
(2)
(23)
(2)
(10)
(4)
(2)
(2)
(2)
(11)
(2)
(2)
(2)
(2)
(43)
(2)
(4)
0 of 1000
(1)
(1)
(3)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(39)
(2)
(1)
(8)
(16)
(1)
(4)
(4)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(2)
(1)
(1)
(3)
(23)
(1)
(1)
(8)
(2)
(1)
(11)
(1)
(1)
(1)
(15)
(1)
(1)
(14)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(3)
(8)
(21)
(1)
(1)
(9)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(16)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(1)
(2)
(7)
(1)
(1)
(5)
(1)
(8)
(2)
(5)
(10)
(2)
(1)
(1)
(2)
(2)
(2)
(22)
(3)
(4)
(4)
(4)
(3)
(1)
(22)
(1)
(7)
(1)
(4)
(2)
(2)
(1)
(4)
(4)
(2)
(32)
(2)
(1)
(1)
(1)
(6)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(31)
(3)
(1)
(5)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(2)
(1)
(7)
(1)
(4)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(2)
(2)
(3)
(1)
(7)
(1)
(2)
(1)
(1)
(10)
(10)
(1)
(11)
(2)
(6)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(9)
(4)
(2)
(1)
(1)
(1)
(5)
(8)
(1)
(1)
(5)
(7)
(1)
(1)
(1)
(1)
(3)
(2)
(2)
(1)
(12)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(2)
(1)
(51)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(15)
(1)
(4)
(8)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(4)
(7)
(1)
(3)
(3)
(1)
(4)
(4)
(1)
(1)
(3)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(14)
(20)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(12)
(1)
(1)
(1)
(1)
(9)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(7)
(1)
(11)
(1)
(2)
(2)
(1)
(1)
(1)
(13)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(7)
(2)
(1)
(1)
(1)
(4)
(3)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(21)
(2)
(1)
(3)
(7)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(15)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(34)
(2)
(1)
(2)
(8)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(15)
(1)
(1)
(1)
(5)
(1)
(13)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(14)
(9)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(37)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(4)
(2)
(10)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(5)
(3)
(2)
(2)
(1)
(1)
(4)
(6)
(8)
(1)
(6)
(1)
(2)
(1)
(3)
(5)
(2)
(4)
(2)
(5)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(11)
(2)
(1)
(3)
(1)
(4)
(2)
(1)
(12)
(2)
(2)
(6)
(1)
(9)
(2)
(1)
(2)
(1)
(7)
(7)
(1)
(1)
(2)
(1)
(11)
(8)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(54)
(2)
(4)
(4)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(6)
(9)
(3)
(1)
(1)
(1)
(1)
(2)
(2)
(3)
(1)
(1)
(4)
(1)
(3)
(1)
(1)
(6)
(3)
(2)
(2)
(1)
(1)
(1)
(4)
(7)
(2)
(4)
(1)
(8)
(1)
(1)
(25)
(1)
(1)
(10)
(17)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(14)
(4)
(3)
(2)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(18)
(1)
(2)
(1)
(1)
(7)
(1)
(2)
(10)
(1)
(1)
(1)
(1)
(30)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(3)
(2)
(1)
(3)
(1)
(2)
(1)
(19)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(30)
(5)
(1)
(11)
(3)
(1)
(1)
(2)
(1)
(2)
(2)
(8)
(1)
(1)
(1)
(1)
(1)
(7)
(4)
(2)
(1)
(4)
(2)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(8)
(2)
(1)
(1)
(2)
(45)
(1)
(1)
(7)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(10)
(1)
(1)
(1)
(10)
(1)
(1)
(13)
(1)
(8)
(7)
(2)
(2)
(1)
(8)
(8)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(7)
(8)
(2)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(10)
(1)
(1)
(2)
(1)
(2)
(1)
(3)
(5)
(4)
(1)
(2)
(2)
(1)
(1)
(9)
(1)
(2)
(2)
(10)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(1)
(4)
(2)
(2)
(26)
(1)
(1)
(24)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(4)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(5)
(4)
(2)
(2)
(1)
(1)
(11)
(3)
(1)
(4)
(1)
(1)
(5)
(1)
(2)
(9)
(1)
(1)
(6)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
0 of 897
(2)
(1)
(1)
(3)
(1)
(1)
(2)
(2)
(5)
(24)
(3)
(4)
(6)
(1)
(16)
(21)
(9)
(1)
(1)
(1)
(1)
(6)
(3)
(1)
(4)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(8)
(1)
(3)
(6)
(1)
(1)
(2)
(14)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(29)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(50)
(113)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(2)
(2)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(4)
(1)
(1)
(1)
(5)
(1)
(11)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(6)
(1)
(1)
(8)
(1)
(2)
(7)
(5)
(1)
(1)
(5)
(2)
(6)
(1)
(1)
(1)
(12)
(1)
(9)
(2)
(1)
(5)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(4)
(3)
(4)
(1)
(16)
(11)
(1)
(8)
(6)
(1)
(3)
(1)
(5)
(1)
(3)
(25)
(3)
(8)
(1)
(1)
(1)
(30)
(4)
(6)
(1)
(44)
(30)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(10)
(14)
(2)
(10)
(1)
(90)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(46)
(4)
(3)
(2)
(66)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(83)
(1)
(1)
(1)
(2)
(53)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(3)
(2)
(6)
(9)
(1)
(10)
(1)
(1)
(2)
(3)
(6)
(2)
(1)
(5)
(4)
(1)
(3)
(2)
(1)
(1)
(13)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(22)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(4)
(9)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(2)
(3)
(3)
(1)
(2)
(10)
(1)
(6)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(3)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(13)
(1)
(14)
(547)
(1)
(1)
(1)
(6)
(1)
(3)
(1)
(4)
(10)
(1)
(15)
(11)
(14)
(1)
(4)
(4)
(1)
(2)
(2)
(5)
(1)
(4)
(1)
(162)
(1)
(5)
(1)
(3)
(7)
(3)
(1)
(33)
(2)
(14)
(3)
(3)
(9)
(2)
(1)
(10)
(1)
(2)
(30)
(6)
(1)
(4)
(4)
(5)
(2)
(7)
(1)
(6)
(2)
(1)
(19)
(15)
(1)
(1)
(9)
(5)
(1)
(2)
(2)
(18)
(3)
(5)
(46)
(2)
(1)
(2)
(3)
(2)
(1)
(3)
(4)
(1)
(5)
(1)
(1)
(4)
(3)
(1)
(1)
(7)
(2)
(2)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(3)
(2)
(3)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
0 of 463
(1)
(74)
(1)
(1)
(1624)
(32)
(7)
(8)
(1)
(14)
(102)
(200)
(10)
(11)
(32)
(1292)
(1)
(39)
(2)
(2)
(63)
(1)
(1)
(1)
(1)
0 of 25
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 17
(1)
0 of 1
Showing 641 - 660 of 2197 results
  • Next steps
    Next steps
    Rao, Agam
    May 5, 2021 | ACIP: Rabies
    04-Rabies-Rao-508.pdf
    Public Domain
  • Rabies preexposure prophylaxis and children
    Rabies pre-exposure prophylaxis and children
    Rao, Agam
    May 5, 2021 | ACIP: Rabies
    02-Rabies-Rao-508.pdf
    Public Domain
  • Characteristics of officebased physician visits 2018
    Characteristics of office-based physician visits, 2018
    Ashman, Jill J. ;
    Santo, Loredana
    05/04/2021 | NCHS Data Briefs
    In 2018, 85% of adults and 96% of children in the United States had a usual place to receive health care (1,2). Most children and adults listed a doctor's office as the usual place they received care (1,2). In 2018, an estimated 860.4 million office-based physician visits occurred in the United States (3,4). This report examines visit rates by age ...
    Supporting Files Public Domain
  • The Advisory Committee on Immunization Practices Interim Recommendation for Use of PfizerBioNTech COVID19 Vaccine in Adolescents Aged 1215 Years United States May 2021
    The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
    Wallace, Megan ;
    Woodworth, Kate R.
    May 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On Dece ...
    Supporting Files Public Domain
  • National Vital Statistics System Division of Vital Statistics Newsletter May 2021
    National Vital Statistics System Division of Vital Statistics Newsletter [ May 2021]
    National Center for Health Statistics (U.S.). Division of Vital Statistics.  ...
    May 2021 | National Vital Statistics System
    Inside this issue – Important reminder regarding the 2021 VSCP Annual Meeting Notable report on Changes in Births to New York City Residents Occurring Outside New York City, by Race and Hispanic Origin of the Mother Information regarding the Vital Statistics Modernization Community of Practice Video and more…
    Public Domain
  • Overview of Janssens SingleDose COVID19 vaccine Ad26COV2S
    Overview of Janssen’s Single-Dose COVID-19 vaccine, Ad26.COV2.S
    Douoguih, Macaya
    February 28, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    28-03-01/02-COVID-Douoguih.pdf
    Public Domain
  • Policy question Should vaccination with the Janssen COVID19 vaccine 1dose IM be recommended for persons 18 years of age and older under an emergency use authorization
    Policy question : Should vaccination with the Janssen COVID-19 vaccine (1-dose, IM) be recommended for persons 18 years of age and older under an emergency use authorization?
    United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group.
    February 28, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    05-COVID-Oliver.pdf
    Public Domain
  • Grading of recommendations assessment development and evaluation GRADE Janssen COVID19 vaccine
    Grading of recommendations, assessment, development, and evaluation (GRADE) : Janssen COVID-19 vaccine
    Gargano, Julia W.
    February 28, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    03-COVID-Gargano.pdf
    Public Domain
  • EtR framework Janssen COVID19 vaccine
    EtR framework : Janssen COVID-19 vaccine
    Oliver, Sara E.
    February 28, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    04-COVID-Oliver.pdf
    Public Domain
  • ACIP COVID19 Vaccines Work Group February 28 2021
    ACIP COVID-19 Vaccines Work Group, February 28, 2021
    Bell, Beth P.
    February 28, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    01-COVID-Bell.pdf
    Public Domain
  • Updated Recommendations From the Advisory Committee on Immunization Practices for Use of the Janssen Johnson Johnson COVID19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients United States April 2021
    Updated Recommendations From the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
    MacNeil, Jessica R. ;
    Su, John R.
    April 27, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? On April 13, 2021, CDC and the Food and Drug Administration (FDA) recommended pausing use of the Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome (TTS) among vaccine recipients.What is added by this report? On April 23, the Advisory Committee on Immunization Practices conclu ...
    Supporting Files Public Domain
  • Advisory Committee on Immunization Practices ACIP summary report December 1 2020 Atlanta Georgia
    Advisory Committee on Immunization Practices (ACIP) summary report : December 1, 2020, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices.
    April 26, 2021 | ACIP: Meeting Agenda, Minutes, etc.
    Publication date from document properties.min-2020-12-1-508.pdf
    Public Domain
  • Projected risks and health benefits of vaccination against herpes zoster and related complications interim results
    Projected risks and health benefits of vaccination against herpes zoster and related complications : interim results
    Prosser, Lisa A.
    February 25, 2021 | ACIP: Herpes Zoster
    03-Zoster-Vaccines-Prosser.pdf
    Public Domain
  • Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among adults United States
    Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among adults, United States
    Gierke, Ryan
    February 25, 2021 | ACIP: Pneumococcal
    02-Pneumococcal-Gierke.pdf
    Public Domain
  • Zoster vaccines session Introduction
    Zoster vaccines session : Introduction
    Lee, Grace M.
    February 25, 2021 | ACIP: Herpes Zoster
    01-Zoster-Vaccines-Lee.pdf
    Public Domain
  • Considerations for use of PCV15 and PCV20 in US adults
    Considerations for use of PCV15 and PCV20 in U.S. adults
    Kobayashi, Miwako
    February 25, 2021 | ACIP: Pneumococcal
    05-Pneumococcal-Kobayashi.pdf
    Public Domain
  • Risk of GuillainBarre syndrome GBS following recombinant zoster vaccine RZV
    Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine (RZV)
    Forshee, Robert A.
    February 25, 2021 | ACIP: Herpes Zoster
    02-Zoster-Vaccines-Forshee.pdf
    Public Domain
  • V114 an investigational 15valent pneumococcal polysaccharide conjugate vaccine PCV key results of the adult clinical development program
    V114 : an investigational 15-valent pneumococcal polysaccharide conjugate vaccine (PCV) : key results of the adult clinical development program
    Buchwald, Ulrike K.
    February 25, 2021 | ACIP: Pneumococcal
    04-Pneumococcal-Buchwald.pdf
    Public Domain
  • 20valent pneumococcal conjugate vaccine PCV20 phase 3 in adults
    20-valent pneumococcal conjugate vaccine (PCV20) phase 3 in adults
    Watson, Wendy
    February 25, 2021 | ACIP: Pneumococcal
    03-Pneumococcal-Watson.pdf
    Public Domain
  • Influenza updates and WG considerations
    Influenza updates and WG considerations
    Grohskopf, Lisa A.
    February 25, 2021 | ACIP: Influenza
    02-influenza-grohskopf.pdf
    Public Domain
641 - 660 / 2197